CLX The Clorox Company

CL's innovation, premiumization and emerging-market expansion are strengthening its brands and creating avenues for long-term growth.

Clorox (CLX) has put its latest acquisition to work, launching the Clorox Purell ProCare health and hygiene platform. The new platform combines CloroxPro with GOJO under a unified offering for professional and healthcare customers. For investors, the Clorox Purell ProCare launch lands at a tricky moment. The share price closed at US$83.80, with a 1-day share price return of 2.44% that sits against a 30-day share price decline of 18.27% and a 1-year total shareholder return that is down...

Clorox has raised its dividend for decades, but a cratering stock price, a payout ratio management calls elevated, and a debt load that ballooned after two major deals raise a pointed question about whether that streak survives fiscal 2027.

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.

Clorox has underperformed the consumer staples sector over the past three months. Wall Street analysts are tepid about its prospects.

PG faces a $1.4 billion after-tax earnings headwind in fiscal 2027 as rising costs, FX pressure and other factors weigh on margins.

Both Clorox and Kimberly-Clark have raised their dividends for years and offer yields above 5%, but one of them is sitting on a payout that its own management quietly admits may not be sustainable.

A fat dividend yield can signal a stock worth buying or a company quietly falling apart, and telling the difference requires looking past the payout itself at the cash flow, debt load, and share price collapse hiding behind the number.

Consumer staples are considered safe havens in turbulent markets due to their inelastic demand profiles. On the other hand, they usually underperform during bull runs, and this paradigm has rung true over the past six months as the sector was flat while the S&P 500 returned 14%.

ADRNY vs. CLX: Which Stock Is the Better Value Option?

CLX's margin management, innovation and IGNITE strategy support growth, while cost pressures and value-conscious consumers challenge its progress.

Clorox has seen its share price fall sharply over recent years, which puts fresh attention on what investors are really paying for its earnings today. With the stock back near levels that some long term holders may not have expected, the key issue is how well the current price lines up with the profits the business is generating. Over the past 5 years, Clorox shares have declined 35.4%, which raises the question of whether the market has reset expectations to match the company’s earnings...

PG's premium valuation, weak price momentum and cost pressures temper its brand strength and innovation-led growth outlook.

When quality dividend stocks drift toward 52-week lows, patient income investors often find their best opportunities hiding in plain sight. Five household names are sitting at beaten-down prices right now, and the yields they are offering demand a closer look.

PG faces a $1.4 billion after-tax earnings headwind in fiscal 2027 as rising costs, FX pressure and other factors weigh on margins.

CLX is using cost savings, ERP optimization and pricing to cushion inflation, but the FY27 gross margin is still projected at 42%.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Clorox (CLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ADRNY vs. CLX: Which Stock Is the Better Value Option?

Reynolds Consumer Products faces rising commodity costs and weaker volumes as pricing and productivity efforts work to protect margins and earnings.

Reynolds Consumer Products is protecting profitability through pricing and productivity, but rising commodity costs and weaker volumes keep its outlook balanced.

Reynolds Consumer Products is using pricing, productivity and cash generation to support earnings despite commodity inflation and softer volumes.

Omega Healthcare, Clorox and Ashland have each raised dividends and offer growth catalysts, making them worth a look for investors seeking both income and total return potential.

Clorox (CLX) has drawn fresh attention after a recent move in its share price, with the stock closing at $106.69. Investors are weighing how this level aligns with the company’s fundamentals and recent returns. See our latest analysis for Clorox. The recent move to a US$106.69 share price comes after a 30 day share price return of 11.66% and a 90 day share price return of 12.18%. However, the 1 year total shareholder return has declined 7.19% and the 5 year total shareholder return has...

Clorox stock has recovered some ground in the short term, yet over the past five years shareholders have seen the share price decline about 23%, while current valuation checks still lean toward the shares looking expensive rather than like a clear bargain. Over the past five years, Clorox has delivered a share price decline of about 23%, which raises questions about how much long term value recent gains are really adding for holders. Management expects supply chain efficiencies from a new...

CLX's GOJO deal boosts fiscal 2027 sales, but inflation, acquisition costs and margin pressure could limit underlying growth.

CLX's GOJO-led growth faces margin pressure, muted core demand and inflation risks, leaving investors focused on a durable recovery.

CLX's rebound faces margin pressure, muted underlying demand and weaker earnings revisions despite GOJO and ERP tailwinds.

CL raised its 2026 profit outlook after a Q2 earnings beat and 140-basis-point margin gain, while higher costs and North America remain risks.

CL enters the second half with better volumes, resilient margins and a higher earnings outlook, but rich valuation and U.S. weakness temper the upside.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

ECL's accelerating High-Tech, Digital and Life Sciences growth supports its outlook, but rising debt and financing costs keep the buy case cautious.

Church & Dwight Co., Inc. (NYSE:CHD) and The Clorox Company (NYSE:CLX) look quite different when it comes to dividends. CHD offers a much lower yield, but its dividend is growing faster. Clorox gives investors far more income today, though the company has been much more conservative with recent increases. Church & Dwight Co., Inc. (NYSE:CHD) […]

As Clorox has underperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

ENR trades at a steep discount, but weak earnings, margin pressure and soft battery demand challenge the case for a rebound.

Clorox’s second quarter generated a positive response from investors, as revenue surpassed analyst expectations despite a 2% year-over-year decline. Management attributed the quarter’s performance to targeted improvements in product superiority, focused brand investments, and effective promotional execution in key categories. CEO Linda Rendle noted that, “the majority of our businesses are performing at or above expectations,” while acknowledging operational challenges in segments like Litter an

GOJO acquisition boosts health segment as organic sales decline amid inflation headwinds.

The household cleaning and consumer products maker expects improvements through better planning, lower inventory levels and more automation.

Increasing energy, commodity and supplier costs are significant contributors, along with higher trucking, ocean freight and logistics-related expenses.

NWL vs. CLX: Which Stock Is the Better Value Option?

Clorox (NYSE:CLX) outlined its fiscal 2027 outlook, highlighting ongoing operational headwinds and inflation risks. The company is forecasting net sales growth of 13% to 14% for fiscal 2027, largely tied to the acquisition of GOJO Industries and the Purell brand. Clorox reported fiscal 2026 results that were in line with prior expectations and used the update to detail how the GOJO and Purell integration could affect future revenue and earnings. Clorox enters this update with the stock...

Clorox is a great value for income investors.

Companies In The News Are: ALSN, CLX, AEIS, PFE.

Clorox (CLX) could face slow underlying sales, lower margins and continued pressure in charcoal and

Clorox beats Q4 sales and earnings estimates as GOJO boosts sales, but lower volume and rising costs pressure margins and profits.

Clorox sees fiscal 2027 sales rising on GOJO and ERP comparisons, but inflation, muted categories and value-seeking consumers cloud the recovery.

The cleaning products maker expects adjusted earnings per share of $5.70 to $6.00 for the year, with most sales growth coming from its Purell acquisition

Moby summary of The Clorox Company's Q4 2026 earnings call

Clorox (NYSE:CLX) said it is entering fiscal 2027 with improving market-share trends, a completed enterprise resource planning implementation and a plan to offset more than $200 million in expected supply-chain inflation through productivity initiatives and targeted pricing. Chair and CEO Linda Ren

Although the revenue and EPS for Clorox (CLX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.